Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED (REVIVE)

Vivus

Status and phase: Completed; Phase 3

Conditions: Erectile Dysfunction

Treatments: Drug: placebo; Drug: avanafil

Study type: Interventional

Funder types: Industry

Identifiers

NCT00790751

TA-301

Details and patient eligibility

About

This study is being conducted to compare the safety and efficacy of 3 doses of avanafil to placebo in men with mild to severe erectile dysfunction.

Enrollment: 646 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male subjects, age ≥ 18 years;
• Minimum 6 month history of mild to severe erectile dysfunction;
• Subject is in a monogamous, heterosexual relationship for at least 3 months;
• Subject agrees to make at least 4 attempts at intercourse per month;
• Subject is willing and able to provide informed consent.

Exclusion criteria

• Allergy or hypersensitivity to PDE5 inhibitors;
• History of dose-limiting AEs during therapy with a PDE5 inhibitor or hx of consistent treatment failure with other PDE5 inhibitors for therapy of ED;
• Current or expected use of organic nitrates at any time during the study;
• Previous or current antiandrogen therapy;
• Use of prescription or over-the-counter drugs known to inhibit the activity of CYP3A4 at any time during the study;
• Androgen replacement therapy that has not been stable for at least 3 month;
• Initiation or change in dose of any alpha-blocker within 14 days prior to randomization;
• ED as a result of spinal cord injury or radical prostatectomy;
• Untreated hypogonadism or low serum total testosterone
• History of or predisposition to priapism;
• Any penile implant;
• Elevated PSA, other evidence of prostate cancer, or previous radical prostatectomy;
• History of any malignancy (except basal cell carcinoma or squamous cell carcinoma of the skin successfully treated by curative excision);
• History of type 1 or type 2 diabetes;
• Uncontrolled hypertension;
• Hypotension;
• Orthostatic hypotension;
• Significant cardiovascular disease;
• Abnormal ECG;
• Hepatic or renal impairment;
• Positive STD screen;
• Clinically evident penile lesions, abrasions, or anatomical deformities;
• Urinary tract or bladder infection;
• Use of any treatment for erectile dysfunction other than study drug at any time during the study;
• Participation in another investigational study within 30 days of screening or at any time during this study;
• Previous participation in any other investigational study of avanafil;
• History or current drug, alcohol, or substance abuse;
• Any history of bipolar disorder or psychosis, greater than one lifetime episode of major depression, current depression of moderate or greater severity or antidepressant use that has not been stable for at least 3 months;
• Partners who are < 18 years of age, who are nursing, who are known to be pregnant at screening, who wish to become pregnant during the study period, who have any gynecologic problems or major medical conditions that would limit participation in sexual intercourse;
• Evidence of any other condition by history, physical examination, or laboratory studies that, in the opinion of the investigator, would contraindicate the administration of study medication, affect compliance, interfere with study evaluations, limit study participation, contraindicate sexual activity, or confound the interpretation of study results.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

646 participants in 4 patient groups, including a placebo group

placebo

Placebo Comparator group

Treatment:

Drug: placebo

avanafil 50 mg

Experimental group

Treatment:

Drug: avanafil

Drug: avanafil

Drug: avanafil

avanafil 100 mg

Experimental group

Treatment:

Drug: avanafil

Drug: avanafil

Drug: avanafil

avanafil 200 mg

Experimental group

Treatment:

Drug: avanafil

Drug: avanafil

Drug: avanafil